Epic Bio to Attend Solebury/BMO Private Business Fall Showcase



SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Epic Bio, a biotechnology company developing therapies to modulate gene expression using the compact, non-cutting dCasMINI protein, today announced that the company will participate in the Fall Companies Showcase Solebury/BMO private events, which will take place on Thursday, October 13, 2022, in New York. The event is co-hosted by BMO Capital Markets and Goodwin Law.

Chairman and CEO Amber Salzman, Ph.D. is scheduled to present Oct. 13 at 2:40 p.m. ET. The Company will arrange meetings with selected investors and analysts.

Interested parties can register for the event on the Solebury website, which can be found here.

About Epic Bio

Epic Bio is a leading epigenetic engineering company, harnessing the power of CRISPR without cutting DNA. The company uses its proprietary Gene Expression Modulation System (GEMS) to develop therapies. Through its exclusive license of CasMINI, the most compact Cas DNA-binding protein to work on human cells, the company is developing in vivo therapies with delivery via a single AAV vector. Epic Bio is initially focused on Facioscapulohumeral Muscular Dystrophy (FSHD) and is conducting additional research to treat antitrypsin deficiency (A1AD), heterozygous familial hypocholesterolemia (HeFH), as well as other programs. The company is financially backed by Horizons Ventures and other leading investors. Visit www.epic-bio.com for more information or follow us on Twitter and LinkedIn.

Source link


Comments are closed.